Literature DB >> 31421598

Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)- 786C carriers in schizophrenia-spectrum disorders.

A Zarina Kraal1, Allison C Moll2, Nicole R Arvanitis3, Kristen M Ward3, Ryan J Dougherty4, Tyler B Grove5, Kyle J Burghardt6, Vicki L Ellingrod7.   

Abstract

Although metabolic syndrome and cognitive inefficiencies are well-described common complications of schizophrenia, their association remains inconsistent, potentially due to poorly understood mechanisms underlying their relationship. Variability in the endothelial nitric oxide synthase (eNOS) gene, specifically the T-786C variant, has been separately associated with cognition and metabolic syndrome, with worse outcomes for eNOS-786C carriers likely occurring via negative effects on blood vessel functioning. However, the interaction between eNOS and metabolic syndrome in cognition among adults with schizophrenia is unknown. This study aimed to test the main and interaction effects of the eNOS-786C allele in cognition using hierarchical regression analyses controlling for age, sex, education, race, and antipsychotic exposure. Metabolic syndrome, eNOS T-786C genotype, and cognitive performance were assessed in 226 community-dwelling participants with chronic schizophrenia-spectrum disorders. Results demonstrated a significant interaction between metabolic syndrome and the eNOS-786C allele. Specifically, among eNOS-786C carriers only, metabolic syndrome was independently associated with lower scores in processing speed and verbal fluency, and predicted 12.5% and 15.8% of variance in performance, respectively. These results suggest that the additive negative effects of eNOS-786C and metabolic syndrome on blood vessel functioning may be severe enough to negatively impact cognition. The finding that metabolic syndrome is associated with worse cognition only in the presence of the eNOS-786C allele may clarify extant inconsistencies in the literature. These findings provide preliminary evidence that may inform interventions to reduce cognitive morbidity among adults with schizophrenia.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Genes; Metabolic syndrome; Processing speed; Psychotic disorders; Verbal fluency; eNOS T-786C

Mesh:

Substances:

Year:  2019        PMID: 31421598      PMCID: PMC6707862          DOI: 10.1016/j.jpsychires.2019.07.006

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  35 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

2.  Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men.

Authors:  Ingrid F Metzger; Debora C Souza-Costa; Aline S Marroni; Sabrina Nagassaki; Zeruesenay Desta; David A Flockhart; Jose E Tanus-Santos
Journal:  Pharmacogenet Genomics       Date:  2005-08       Impact factor: 2.089

3.  Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants.

Authors:  J E Tanus-Santos; M Desai; D A Flockhart
Journal:  Pharmacogenetics       Date:  2001-11

4.  Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T-->C mutation associated with coronary spastic angina.

Authors:  Y Miyamoto; Y Saito; M Nakayama; Y Shimasaki; T Yoshimura; M Yoshimura; M Harada; N Kajiyama; I Kishimoto; K Kuwahara; J Hino; E Ogawa; I Hamanaka; S Kamitani; N Takahashi; R Kawakami; K Kangawa; H Yasue; K Nakao
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

5.  The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

Authors:  Jonathan M Meyer; Henry A Nasrallah; Joseph P McEvoy; Donald C Goff; Sonia M Davis; Miranda Chakos; Jayendra K Patel; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-08-24       Impact factor: 4.939

6.  Disclosure of APOE genotype for risk of Alzheimer's disease.

Authors:  Robert C Green; J Scott Roberts; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Tamsen Brown; Susan LaRusse Eckert; Melissa Butson; A Dessa Sadovnick; Kimberly A Quaid; Clara Chen; Robert Cook-Deegan; Lindsay A Farrer
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

7.  Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice.

Authors:  Stéphane Cook; Olivier Hugli; Marc Egli; Peter Vollenweider; Rémy Burcelin; Pascal Nicod; Bernard Thorens; Urs Scherrer
Journal:  Swiss Med Wkly       Date:  2003-06-28       Impact factor: 2.193

8.  The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

Authors:  Richard S E Keefe; Terry E Goldberg; Philip D Harvey; James M Gold; Margaret P Poe; Leigh Coughenour
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

9.  Inducible and endothelial nitric oxide synthase expression in human atherogenesis: an immunohistochemical and ultrastructural study.

Authors:  Ida Perrotta; Elvira Brunelli; Alfonso Sciangula; Valeria Zuccalà; Giuseppe Donato; Sandro Tripepi; Gian Luca Martinelli; Mauro Cassese
Journal:  Cardiovasc Pathol       Date:  2008-10-01       Impact factor: 2.185

10.  Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.

Authors:  Jonathan M Meyer; Vicki G Davis; Donald C Goff; Joseph P McEvoy; Henry A Nasrallah; Sonia M Davis; Robert A Rosenheck; Gail L Daumit; John Hsiao; Marvin S Swartz; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2008-02-06       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.